In a Victory for the Free Market, FDA Approves New Schizophrenia Drug
Despite billions of taxpayer dollars spent on mental illness research, Cobenfy was developed by a private biopharmaceutical ...
scrippsnews30m
FDA approves first new medication to treat schizophrenia in more than 30 years
People with schizophrenia will soon have a new treatment option after the FDA approved its first new treatment for the mental ...
Business Wire1h
U.S. Food and Drug Administration Approves Bristol Myers Squibb’s COBENFY™ (xanomeline and trospium chloride), a First-In-Class Muscarinic Agonist for the Treatment of ...
U.S. FDA Approves Bristol Myers Squibb’s COBENFY, a First-In-Class Muscarinic Agonist for the Treatment of Schizophrenia in Adults ...
Monthly Prescribing Reference1h
Cobenfy Approved for Adult Patients with Schizophrenia
Xanomeline and trospium chloride is a first-in-class medication that selectively targets the M1 and M4 receptors without blocking D2 receptors.
Boise State Public Radio2h
A new kind of drug for schizophrenia promises fewer side effects
A medicine that sidesteps the brain's dopamine receptors to reach different targets represents a new approach to ...
New schizophrenia drug gets FDA approval, taking novel approach to treating brain disorder
On Thursday, the U.S. Food and Drug Administration approved COBENFY, an oral medication that marks the first new class of ...
US FDA approves GE HealthCare's diagnostic drug for heart disease
The U.S. Food and Drug Administration approved GE HealthCare's diagnostic drug for use in detection of coronary artery ...
These Stocks Are Moving the Most Today: Bristol Myers, Costco, EchoStar, Cassava, DJT, Wynn, HP Inc., Acadia Healthcare, and More
Bristol Myers trades higher after the FDA approves an oral medication for schizophrenia in adults, fiscal fourth-quarter ...
MM&M6h
Bristol Myers Squibb wins FDA approval for first new schizophrenia drug in 30 years
Cobenfy targets cholinergic receptors instead of the dopamine receptors long addressed in current schizophrenia drugs — a new treatment approach to the disease.
btimesonline8h
FDA Approves Bristol Myers Squibb’s Cobenfy, First Novel Schizophrenia Drug in 70 Years
Bristol Myers Squibb received U.S. Food and Drug Administration (FDA) approval on Thursday for its groundbreaking ...
The FDA just approved Bristol Myers Squibb's groundbreaking schizophrenia treatment
The U.S. Food and Drug Administration (FDA) on Thursday approved Bristol Myers Squibb’s (BMY) highly anticipated ...